Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours
Source abstract
Abstract
This work demonstrates gastric mucin-triggered nanocarrier disassembly for release of antisense oligonucleotides and consequent unassisted cellular entry as a novel oral delivery strategy. A fluorescence activation-based reporter system was used to investigate the interaction and mucin-mediated disassembly of chitosan-based nanocarriers containing a 13-mer DNA oligonucleotide with a flanked locked RNA nucleic acid gapmer design. Gastric mucins were shown to trigger gapmer release from nanocarriers that was dependent on the interaction time, mucin concentration and N : P ratio with a maximal release at N : P 10. In contrast to siRNA, naked gapmers exhibited uptake into mucus producing HT-MTX mono-cultures and HT-MTX co-cultured with the carcinoma epithelial cell line Caco-2. Importantly, in vivo gapmer uptake was observed in epithelial tissue 30 min post-injection in murine intestinal loops. The findings present a mucosal design-based system tailored for local delivery of oligonucleotides that may maximize the effectiveness of gene silencing therapeutics within tumours at mucosal sites.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Interdisciplinary Nanoscience Center (iNANO)
Department of Molecular Biology and Genetics
Aarhus University
Aarhus C, Denmark
Department of Biomedicine
Funding
Strategiske Forskningsrad
References (46)
Show source-provided references
1. Cancer Classification of the National Cancer Institute, http://training.seer.cancer.gov/disease/categories/classification.html
2. Malvezzi · Ann. Oncol. · 2015 · 1
3. Miele · Int. J. Nanomed. · 2012 · 7 · 3637
4. Ballarín-González · Cancer Lett. · 2014 · 352 · 6610.1016/j.canlet.2013.09.023 ↗
5. Wu · Sci. Transl. Med. · 2014 · 6 · 240ps710.1126/scitranslmed.3008362 ↗
6. Howard · Expert Opin. Biol. Ther. · 2007 · 7 · 181110.1517/14712598.7.12.1811 ↗
7. Howard · Adv. Drug Delivery Rev. · 2009 · 61 · 71010.1016/j.addr.2009.04.001 ↗
8. Olsesen · Drug Delivery Transl. Res. · 2014 · 4 · 410.1007/s13346-013-0156-9 ↗
9. Linden · Mucosal Immunol. · 2008 · 1 · 18310.1038/mi.2008.5 ↗
10. Lai · Adv. Drug Delivery Rev. · 2009 · 61 · 8610.1016/j.addr.2008.09.012 ↗
11. Bansil · Front. Immunol. · 2013 · 310
12. Draz · Theranostics · 2014 · 4 · 87210.7150/thno.9404 ↗
13. Illum · Adv. Drug Delivery Rev. · 2001 · 51 · 8110.1016/S0169-409X(01)00171-5 ↗
14. Martirosyan · Adv. Genet. · 2014 · 88 · 32510.1016/B978-0-12-800148-6.00011-0 ↗
15. Howard · Mol. Ther. · 2006 · 14 · 47610.1016/j.ymthe.2006.04.010 ↗
16. Liu · Biomaterials · 2007 · 28 · 128010.1016/j.biomaterials.2006.11.004 ↗
17. Nielsen · Pharm. Res. · 2010 · 27 · 252010.1007/s11095-010-0255-y ↗
18. Ballarín-González · Mol. Ther. Nucleic Acids · 2013 · 2 · e7610.1038/mtna.2013.2 ↗
19. Thomsen · Nanoscale · 2014 · 6 · 1254710.1039/C4NR01584C ↗
20. Stein · Nucleic Acids Res. · 2010 · 38 · e310.1093/nar/gkp841 ↗
21. Moschos · Mol. Ther. · 2011 · 19 · 216310.1038/mt.2011.206 ↗
22. Wahlestedt · Proc. Natl. Acad. Sci. U. S. A. · 2000 · 97 · 563310.1073/pnas.97.10.5633 ↗
23. Castanotto · Curr. Opin. Oncol. · 2014 · 26 · 58410.1097/CCO.0000000000000127 ↗
24. Moreno · Front. Chem. · 2014 · 2 · 8710.3389/fchem.2014.00087 ↗
25. Martirosyan · Nanotoxicology · 2014 · 8 · 57310.3109/17435390.2013.812258 ↗
26. The International Pharmacopoeia, 5th edition http://apps.who.int/phint/en/p/docf/
27. Andersen · Methods Mol. Biol. · 2009 · 555 · 7710.1007/978-1-60327-295-7_6 ↗
28. Moeller · Kidney Int. · 2009 · 75 · 29510.1038/ki.2008.505 ↗
29. Matsuo · Gut · 1997 · 40 · 78210.1136/gut.40.6.782 ↗
30. Zhou · J. Am. Chem. Soc. · 2012 · 134 · 780310.1021/ja300176w ↗
31. Ho · J. Mater. Chem. B · 2013 · 1 · 242510.1039/c3tb20146e ↗
32. De Campos · Eur. J. Pharm. Sci. · 2003 · 20 · 7310.1016/S0928-0987(03)00178-7 ↗
33. Mahler · J. Nutr. Biochem. · 2009 · 20 · 49410.1016/j.jnutbio.2008.05.006 ↗
34. Kurreck · Nucleic Acids Res. · 2002 · 30 · 191110.1093/nar/30.9.1911 ↗
35. Ensign · Adv. Mater. · 2012 · 24 · 388710.1002/adma.201201800 ↗
36. Okamoto · J. Gastroenterol. · 2004 · 39 · 110.1007/s00535-003-1259-8 ↗
37. Niebel · J. Controlled Release · 2012 · 160 · 65910.1016/j.jconrel.2012.03.004 ↗
38. Lautenschlager · Eur. J. Pharm. Biopharm. · 2013 · 85 · 57810.1016/j.ejpb.2013.09.016 ↗
39. Wilson · Nat. Mater. · 2010 · 9 · 92310.1038/nmat2859 ↗
40. Prados · BioDrugs · 2013 · 27 · 31710.1007/s40259-013-0019-4 ↗
41. Kufe · Nat. Rev. Cancer · 2009 · 9 · 87410.1038/nrc2761 ↗
42. Debunne · Acta Chir. Belg. · 2013 · 113 · 38510.1080/00015458.2013.11680951 ↗
43. Torres · Curr. Pharm. Des. · 2012 · 18 · 247210.2174/13816128112092472 ↗
44. Roulois · BioMed Res. Int. · 2013 · 871936
45. Horm · Cell Adhes. Migr. · 2013 · 7 · 18710.4161/cam.23131 ↗
46. Spicer · J. Biol. Chem. · 1995 · 270 · 3009310.1074/jbc.270.50.30093 ↗